These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 10473883

  • 1. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey.
    Aydinok Y, Nisli G, Kavakli K, Coker C, Kantar M, Cetingül N.
    Acta Haematol; 1999; 102(1):17-21. PubMed ID: 10473883
    [Abstract] [Full Text] [Related]

  • 2. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y, Nisli G, Kavakli K.
    Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
    [No Abstract] [Full Text] [Related]

  • 3. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Hemoglobin; 2011 Jul; 35(3):206-16. PubMed ID: 21599433
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

  • 5. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
    Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A.
    Br J Haematol; 2003 Jun 13; 121(6):938-48. PubMed ID: 12786807
    [Abstract] [Full Text] [Related]

  • 6. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.
    Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A.
    Br J Haematol; 2003 Apr 13; 121(1):187-9. PubMed ID: 12670352
    [Abstract] [Full Text] [Related]

  • 7. Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence?
    Kidson-Gerber G, Lindeman R.
    Br J Haematol; 2008 Aug 13; 142(4):679-80. PubMed ID: 18537970
    [No Abstract] [Full Text] [Related]

  • 8. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients.
    Mirbehbahani N, Jahazi A, Rahim Abad HH.
    Hematology; 2012 May 13; 17(3):183-6. PubMed ID: 22664119
    [Abstract] [Full Text] [Related]

  • 9. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, Loubser MD, Koren G, Roifman CM, Olivieri NF.
    Br J Haematol; 1997 Sep 13; 98(3):597-600. PubMed ID: 9332313
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Sep 13; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 11. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Sep 13; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 12. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ, Kolnagou A.
    Lancet; 2003 Jan 11; 361(9352):184. PubMed ID: 12531621
    [No Abstract] [Full Text] [Related]

  • 13. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG.
    Lancet; 2003 Jan 11; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract] [Full Text] [Related]

  • 14. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.
    Br J Haematol; 2009 Apr 11; 145(2):245-54. PubMed ID: 19236376
    [Abstract] [Full Text] [Related]

  • 15. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ.
    Lancet; 2003 Jan 11; 361(9352):183; author reply 183-4. PubMed ID: 12531619
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N, Ali S, Butt MA.
    J Ayub Med Coll Abbottabad; 2014 Jan 11; 26(3):297-300. PubMed ID: 25671931
    [Abstract] [Full Text] [Related]

  • 17. Combined oral and parenteral iron chelation in beta thalassaemia major.
    Balveer K, Pyar K, Wonke B.
    Med J Malaysia; 2000 Dec 11; 55(4):493-7. PubMed ID: 11221163
    [Abstract] [Full Text] [Related]

  • 18. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N.
    Hematology; 2007 Dec 11; 12(6):577-85. PubMed ID: 17852442
    [Abstract] [Full Text] [Related]

  • 19. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Fischer R, Engelhardt R.
    Lancet; 2003 Jan 11; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
    [No Abstract] [Full Text] [Related]

  • 20. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
    Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M.
    Eur J Haematol; 2007 Jan 11; 78(1):52-7. PubMed ID: 17042760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.